TME Pharma NV (XPAR:ALTME) Interest Income : €0.40 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. TME Pharma NV's interest income for the six months ended in Dec. 2023 was €0.15 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2023 was €0.40 Mil.

TME Pharma NV Interest Income Historical Data

The historical data trend for TME Pharma NV's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Interest Income Chart

TME Pharma NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Income

Get a 7-Day Free Trial

3.09

0.42

0.32

0.30

0.40

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Income	Get a 7-Day Free Trial													0.19	0.20	0.11	0.25	0.15

TME Pharma NV Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.40 Mil.

TME Pharma NV (XPAR:ALTME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines